GLYC - グリコ・ミメティックス (GlycoMimetics Inc.) グリコ・ミメティックス

 GLYCのチャート


 GLYCの企業情報

symbol GLYC
会社名 GlycoMimetics Inc (グリコ・ミメティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GlycoMimetics Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate GMI-1070 (Rivipansel) for the treatment of vaso-occlusive crisis (VOC) a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271 a specific E-selectin inhibitor to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate GMI-1359 that targets both E-selectin and a chemokine receptor CXCR4. The Company is also advancing other preclinical-stage programs which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.   グリコ・ミメティックスは希少薬の発見と開発を行う米国のバイオ医薬品会社。鎌状赤血球病患者の血管閉鎖性発作の治療薬GMI-1070、急性骨髄性白血病と血液凝固障害の治療薬GMI-1271の治験を行う。また、緑膿菌毒性因子をタ―ゲットにした治療薬の開発を行う。   
本社所在地 9708 Medical Center Drive Rockville MD 20850 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-243-1201
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.glycomimetics.com
nasdaq_url https://www.nasdaq.com/symbol/glyc
adr_tso
EBITDA EBITDA(百万ドル) -41.46510
終値(lastsale) 13.62
時価総額(marketcap) 586439976.54
時価総額 時価総額(百万ドル) 609.26030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 379.82560
当期純利益 当期純利益(百万ドル) -39.99956
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense) General_Administrative Expe increase of 26% to $4.3M (expense) Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59.

 GLYCのテクニカル分析


 GLYCのニュース

   Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML  2021/03/04 13:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China. “Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that A
   GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020  2021/03/02 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million. “During 2020, we remained on track to complete enrollment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to have strong support from c
   GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences  2021/02/26 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows: Cowen 41st Annual Health Care Conference March 1 – March 4, 2021 Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in
   GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2  2021/02/23 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all c
   GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer  2021/02/23 14:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our ma
   Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML  2021/03/04 13:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China. “Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that A
   GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020  2021/03/02 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the fourth quarter and year ended December 31, 2020, and highlighted recent Company events, including several accomplishments reported to date in 2021. Cash and cash equivalents at December 31, 2020 were $137.0 million. “During 2020, we remained on track to complete enrollment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to have strong support from c
   GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences  2021/02/26 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows: Cowen 41st Annual Health Care Conference March 1 – March 4, 2021 Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in
   GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2  2021/02/23 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1034166. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all c
   GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer  2021/02/23 14:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our ma
   Sickle Cell Anemia Therapeutics Market Explain By Major Players Bristol-Myers Squibb, GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast Therapeutics  2021/01/18 12:04:20 OpenPR
Coherent Market Insights released a new market study on 2020-2027 Sickle Cell Anemia Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing
   New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition  2020/12/07 21:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data reinforcing a now comprehensive set of findings that underscore the improvement of rivipansel when administered early during an acute vaso-occlusive crisis (VOC) in individuals with sickle cell disease (SCD). The new data were part of an analysis of an Open Label Extension (OLE) trial of rivipansel, designed
   GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences  2020/11/10 21:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows: Stifel 2020 Virtual Healthcare Conference November 16-18, 2020 GlycoMimeti
   GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020  2020/11/06 12:30:00 Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company
   Earnings Scheduled For November 6, 2020  2020/11/06 08:33:52 Benzinga
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ: AY ) is likely to report quarterly earnings at $0.66 per share on revenue of $288.39 million. • AES (NYSE: AES ) is projected to report quarterly earnings at $0.43 per share on revenue of $2.70 billion. • Amphastar Pharmaceuticals (NASDAQ: AMPH ) is likely to report quarterly earnings at $0.14 per share on revenue of $91.26 million. • Assertio Holdings (NASDAQ: ASRT ) is projected to report quarterly earnings at $0.01 per share on revenue of $32.50 million. • AYRO (NASDAQ: AYRO ) is likely to report earnings for its third quarter. • Calumet Specialty (NASDAQ: CLMT ) is projected to report quarterly loss at $0.38 per share on revenue of $531.73 million. • Colony Capital (NYSE: CLNY ) is estimated to report quarterly loss at $0.20 per share on revenue of $27.25 million. • Coty (NYSE: COTY ) is likely to report quarterly loss at $0.05 per share on revenue of $1.08 billion. • Cheniere Energy Partners, LP Cheniere Energy Partners, LP Common Units (AMEX: CQP ) is estimated to report quarterly earnings at $0.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 グリコ・ミメティックス GLYC GlycoMimetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)